SCHEMBL1102282

SCHEMBL1102282

CC1(C)c2cc(NC(N)=O)ccc2-c2[nH]c3c(F)c(-c4ccc(N5CCCCC5)cc4)ccc3c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 7/20 0.49
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
IKBKB O14920 1/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
MAPT P10636 4/20 0.37
TSHR P16473 1/20 0.37
ROCK1 Q13464 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
GFER P55789 1/20 0.36
ACVRL1 P37023 1/20 0.35
ACVR1 Q04771 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102283 0.91 MPL (0.48) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1091882 0.85 MPL (0.66) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1102143 0.82 MPL (0.57) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1102197 0.79 MPL (0.48) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1102077 0.75 MPL (0.69) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1102085 0.73 MPL (0.57) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1091702 0.73 GAA (0.39) MPLSMN1; SMN2MAPK1MAPTGFER
SCHEMBL1102236 0.71 MPL (0.49) MPLNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1091719 0.69 MPL (0.67) MPLGAAKDM4E
SCHEMBL1102116 0.69 MPL (0.68) MPLNPC1RAB9ATP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO MPL 1/4885NPC1 3522/4885RAB9A 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.